DiaMedica Therapeutics, Inc. $DMAC Shares Purchased by Paragon Associates & Paragon Associates II Joint Venture

Paragon Associates & Paragon Associates II Joint Venture raised its position in shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) by 34.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 875,000 shares of the company’s stock after acquiring an additional 225,000 shares during the period. DiaMedica Therapeutics makes up approximately 10.7% of Paragon Associates & Paragon Associates II Joint Venture’s investment portfolio, making the stock its 4th largest position. Paragon Associates & Paragon Associates II Joint Venture owned about 1.69% of DiaMedica Therapeutics worth $6,011,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Police & Firemen s Retirement System of New Jersey acquired a new stake in DiaMedica Therapeutics during the 2nd quarter worth approximately $29,000. Bank of America Corp DE boosted its stake in DiaMedica Therapeutics by 3,710.3% in the 2nd quarter. Bank of America Corp DE now owns 8,497 shares of the company’s stock valued at $33,000 after purchasing an additional 8,274 shares during the period. Strs Ohio grew its holdings in DiaMedica Therapeutics by 19.7% in the 3rd quarter. Strs Ohio now owns 9,100 shares of the company’s stock valued at $63,000 after buying an additional 1,500 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in DiaMedica Therapeutics in the 2nd quarter valued at $49,000. Finally, Invesco Ltd. bought a new position in DiaMedica Therapeutics during the 2nd quarter worth $54,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Stock Up 1.6%

Shares of DMAC stock opened at $7.71 on Friday. The business has a fifty day simple moving average of $8.21 and a 200 day simple moving average of $7.52. The company has a market cap of $401.54 million, a P/E ratio of -10.86 and a beta of 1.09. DiaMedica Therapeutics, Inc. has a twelve month low of $3.19 and a twelve month high of $10.42.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on DMAC shares. Lake Street Capital reissued a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Cantor Fitzgerald initiated coverage on shares of DiaMedica Therapeutics in a research note on Friday, November 14th. They issued an “overweight” rating on the stock. Wall Street Zen lowered shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.